Polioviruses

Principles and Practice of Pediatric Infectious Diseases, Fourth Edition

Volumn , Issue , 2012, Pages 1168-1172.e1

  Troy, Stephanie B ^a   Maldonado, Yvonne A ^b,c  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880963760     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2702-9.00237-3     Document Type: Chapter

References (34)

1. L Kinnunen, T Pöyry and T Hovi (1992) Genetic diversity and rapid evolution of poliovirus in human hosts. Curr Top Microbiol Immunol 176 49-61.
2. H Horie, S Koike, T Kurata, et al. (1994) Transgenic mice carrying the human poliovirus receptor: new animal models for study of poliovirus neurovirulence. J Virol 68 681-688.
3. R Ren and V Racaniello (1992) Poliovirus spreads from muscle to the central nervous system by neural pathways. J Infect Dis 166 747-752.
4. World Health Assembly (1998) Global Eradication of Poliomyelitis by the Year 2000. Resolution WHA 41.28. Geneva: World Health Organization
5. Centers for Disease Control and Prevention (2010) Progress toward interruption of wild poliovirus transmission – worldwide, 2009. MMWR Morb Mortal Wkly Rep 59 545-550.
6. P Minor (2009) Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 27 2649-2652.
7. H Jenkins, R Aylward, A Gasasira, et al. (2010) Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med 362(25), 2360-2369.
8. M Dalakas and I Illa (1991) Post-polio syndrome: concepts in clinical diagnosis, pathogenesis, and etiology. Adv Neurol 56 495-511.
9. F Rosen (2004) Isolation of poliovirus – John Enders and the Nobel Prize. N Engl J Med 351 1481-1483.
10. P Strebel, R Sutter, S Cochi, et al. (1992) Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 14 568-579.
11. H Markel (2005) April 12, 1955 – Tommy Francis and the Salk vaccine. N Engl J Med 352 1408-1410.
12. Centers for Disease Control and Prevention (2000) Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 49(RR-5), 1-22.
13. P Patriarca, P Wright and T John (1991) Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 13 926-939.
14. Y Maldonado, V Peña-Cruz, M de la Luz Sanchez, et al. (1997) Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. J Infect Dis 175 545-553.
15. H Faden and L Duffy (1992) Effect of concurrent viral infection on systemic and local antibody responses to live attenuated and enhanced-potency inactivated poliovirus vaccines. Am J Dis Child 146 1320-1323.
16. P Strebel, N Ion-Nedelcu, A Baughman, et al. (1995) Intramuscular injections within 30 days of immunization with oral poliovirus vaccine – a risk factor for vaccine-associated paralytic poliomyelitis. N Engl J Med. 332 500-506.
17. P Minor (1992) The molecular biology of poliovaccines. J Gen Virol 73 3065-3077.
18. M Böttiger (1987) A study of the sero-immunity that has protected the Swedish population against poliomyelitis for 25 years. Scand J Infect Dis 19 595-601.
19. T Hovi, K Cantell, A Huovilainen, et al. (1986) Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet 1 1427-1432.
20. E Simoes, B Padmini, M Steinhoff, et al. (1985) Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. Am J Dis Child 139 977-980.
21. A McBean, M Thoms, P Albrecht, et al. (1988) Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol 128 615-628.
22. H Faden, J Modlin, M Thoms, et al. (1990) Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 162 1291-1297.
23. H Faden, L Duffy, M Sun, et al. (1993) Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines. J Infect Dis 168 452-454.
24. R Selvakumar and T John (1987) Intestinal immunity induced by inactivated poliovirus vaccine. Vaccine 5 141-144.
25. I Onorato, J Modlin, A McBean, et al. (1991) Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis 163 1-6.
26. G Zhaori, M Sun, H Faden, et al. (1989) Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines. J Infect Dis 159 1018-1024.
27. N Grassly, H Jafari, S Bahl, et al. (2009) Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J Infect Dis 200 794-801.
28. N Grassly, J Wenger, S Durrani, et al. (2007) Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 369 1356-1362.
29. S Halperin, B Tapiero, F Diaz-Mitoma, et al. (2009) Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12–14 months of age. Vaccine 27 2540-2547.
30. A Mohammed, S AlAwaidy, S Bawikar, et al. (2010) Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 362 2351-2359.
31. S Resik, A Tejeda, P Lago, et al. (2010) Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 201 1344-1352.
32. R Davis, T Lieu, L Mell, et al. (2001) Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics 107 671-676.
33. S Adenyi-Jones, H Faden, M Ferdon, et al. (1992) Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants. J Pediatr 120 686-689.
34. T Harjulehto-Mervaala, T Aro, V Hiilesmaa, et al. (1994) Oral polio vaccination during pregnancy: lack of impact on fetal development and perinatal outcome. Clin Infect Dis 18 414-420.